glp-1 prescriptions growth q1 2025

glp-1 prescriptions growth q1 2025 Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline Monitoring Report: GLP-1 RA Prescribing

Name: glp-1 prescriptions growth q1 2025 Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline Monitoring Report: GLP-1 RA Prescribing
Brand: kozanlarjeotermal.com.tr
SKU: 41664294366
Price: 21.83 USD
Availability: InStock
Rating: 4.605700000000001 (5 reviews)

SKU: 41664294366

4.6

EUR21.83 EUR43.83

Pay in 4 interest-free payments of $5.46 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 21 - Aug 26

Description

Notably, administration of GEP44 resulted in an 80% reduction in food intake and a more profound loss of body weight than what could be achieved in response to treatment with several of the US Food and Drug Administration (FDA)-approved GLP-1RAs, including Ex-4 and liraglutide (LIRA)

One study showed an average weight loss of 27.3 lbs

Comparator Selection : Many trials use placebo comparisons rather than active comparators, limiting understanding of relative effectiveness compared to existing obesity treatments